Neuropsychopharmacology Reports

Neuropsychopharmacology Reports is the open access English journal of the Japanese Society of Neuropsychopharmacology, issued by Wiley and given over to the pharmacology of the central nervous system.《神经精神药理学报告》是日本神经精神药理学会的英文开放获取会刊，由 Wiley 出版，内容集中在中枢神经系统药理学。

Its pages move between bench and clinic, so one issue can hold a receptor binding experiment, a randomised trial of an antidepressant and a study of plasma concentrations in everyday practice.论文在实验台与门诊之间往返，同一期里可以同时出现受体结合实验、抗抑郁药随机试验，以及日常诊疗中的血药浓度研究。

The first volume was numbered 38 and carried the year 2018, a sign that the society kept the count of an earlier series instead of opening at volume one.首卷编号为第 38 卷，年份是 2018 年，这一细节说明学会沿用了更早一套刊物的卷次，并未从第一卷重新起算。

In the 2025 Journal Citation Reports the impact factor stands at 1.9, the five-year value at 2.0, and every article is free to read from the day it appears online.2025 年期刊引证报告中，影响因子为 1.9，五年影响因子为 2.0，每篇文章自上线之日起即可免费阅读。

Scope

• The remit covers how psychoactive drugs act on the brain and how behaviour changes in response, a question the journal follows from molecular pharmacology through to the consulting room.刊物范围覆盖精神活性药物如何作用于脑，以及行为随之发生的变化，这条线索从分子药理学一直延伸到诊室。
• Receptor pharmacology sits near the centre, with work on dopamine, serotonin, glutamate and GABA systems, on transporters and on the second messengers that carry a drug signal inward.受体药理学居于中心位置，研究涉及多巴胺、5-羟色胺与 GABA 等递质系统，也涉及转运体以及把药物信号传入细胞内的第二信使。
• Animal work takes a large share, from rodent models of depression and psychosis to behavioural readouts such as forced swim, prepulse inhibition and social interaction, always with attention to model validity.动物研究占相当篇幅，从抑郁与精神病性症状的啮齿类模型，到强迫游泳、前脉冲抑制与社交互动这类行为读数，模型效度始终受到追问。
• Human psychopharmacology appears through challenge studies, in which a single dose of a drug is given to volunteers or patients and the ensuing mood, cognition or endocrine response is measured.人体精神药理学以药物激发研究的形式出现，给志愿者或患者单次用药，随后测量情绪、认知与内分泌反应。
• Clinical trials form another pillar, covering antidepressants, antipsychotics, mood stabilisers and augmentation strategies, with attention to response rates, remission and the functional outcome that patients notice in ordinary life.临床试验构成另一根支柱，涵盖抗抑郁药、抗精神病药、心境稳定剂与增效策略，关注应答率、缓解率以及患者在日常生活中能察觉的功能结局。
• Pharmacogenetics has a firm place, since variants in CYP2D6 and CYP2C19 alter plasma levels of many psychotropics, and genotype guided dosing is examined against measured concentrations and clinical response.药物遗传学占有稳固位置，CYP2D6 与 CYP2C19 的变异会改变许多精神药物的血药浓度，基因型指导的给药方案要与实测浓度和临床应答对照检验。
• Therapeutic drug monitoring belongs to the same conversation, and reports on assay methods, sampling timing and reference ranges for antipsychotics, antidepressants and mood stabilisers are within scope.治疗药物监测属于同一条讨论线，检测方法、采血时点以及各类精神药物的参考区间都在范围之内。
• Neuroimaging enters through receptor occupancy studies, resting state connectivity and task based functional MRI, while PET work with radioligands links a dose to the fraction of receptors it occupies.神经影像通过受体占据研究、静息态连接与任务态功能磁共振进入刊物，正电子发射断层显像借助放射性配体，把剂量与受体被占据的比例对应起来。
• Electrophysiology runs alongside it, with resting EEG, event related potentials, mismatch negativity and sleep recordings used to test whether a compound reaches its target in the living brain.电生理与影像并行，静息脑电、事件相关电位、失匹配负波以及睡眠记录，用来检验化合物是否抵达活体脑内的靶点。
• Addiction and substance use occupy steady space, from the neurobiology of craving and relapse to trials of substitution treatment for alcohol, nicotine and opioid dependence, and to their long term outcomes.成瘾与物质使用占有稳定版面，从渴求与复发的神经生物学，到酒精、尼古丁与阿片依赖的替代治疗试验，再到这些试验的长期结局。
• Mood disorders and schizophrenia carry much of the clinical load, with papers on the mechanism of action of lithium, on treatment resistant depression and on the metabolic cost of long term antipsychotic use.情绪障碍与精神分裂症承担了大部分临床分量，碳酸锂的作用机制、难治性抑郁以及长期使用抗精神病药的代谢代价都有专文讨论。
• Anxiety, obsessive compulsive disorder and trauma related conditions appear regularly, often through work on serotonergic agents, on augmentation with glutamatergic drugs and on the timing of response.焦虑、强迫与创伤相关障碍时常露面，讨论多围绕 5-羟色胺能药物、谷氨酸能药物增效以及应答出现的时间窗。
• Safety work is treated as science rather than paperwork, and reports on extrapyramidal symptoms, metabolic disturbance, QT prolongation, hyponatraemia and drug interactions are welcome wherever the data are sound.安全性研究被当作科学问题处理，锥体外系症状与代谢紊乱、QT 间期延长以及低钠血症都有人写，药物相互作用同样在列。
• Reviews, systematic reviews and meta analyses give the field its summaries, and short Brief Reports give preliminary findings or single case observations a route into print without a full length manuscript.综述、系统综述与元分析为领域提供汇总，篇幅较短的 Brief Report 则让初步发现或单个病例观察无需写成完整长文即可发表。

History

• The journal opened in 2018 as the society's English language organ, with Wiley handling publication from the first issue and the society holding editorial responsibility for the title.该刊 2018 年作为学会的英文会刊问世，首期起即由 Wiley 出版，学会承担刊物的学术责任。
• Numbering began at volume 38 rather than volume one, and the sequence has run without a break since, so volume 44 belongs to 2024 and volume 46 to 2026, one volume for each calendar year.卷次从第 38 卷开始，此后每年递增一卷，不曾中断，第 44 卷对应 2024 年，第 46 卷对应 2026 年。
• Volume 38 carried four issues, and each of them held between eight and eleven papers, a modest start that still put the whole first year into the indexing services.第 38 卷共四期，每期收录 8 至 11 篇论文，起步规模不大，却让创刊首年整卷进入索引体系。
• Four issues a year has remained the pattern since launch, and the grid runs from issue one to issue four in every volume, the current one included.每年四期的节奏自创刊延续至今，每一卷都从第 1 期排到第 4 期，现行卷次也不例外。
• Only an electronic number was registered, 2574-173X, and Crossref records the same value for print and online, which marks the title as an online only publication with no separate print run.仅登记电子刊号 2574-173X，Crossref 对印刷与电子两种载体给出同一个值，说明该刊只在线上发行，没有独立的纸质版。
• MEDLINE took the title from volume 38 issue 1 of March 2018, the first issue it ever published, and PubMed and PubMed Central have carried the full text since then.MEDLINE 自 2018 年 3 月的第 38 卷第 1 期起收录，那正是创刊号，PubMed 与 PubMed Central 此后一直提供全文。
• Every article is free at the point of reading, gold open access stands at 100 percent in the 2025 release, and authors meet an article processing charge instead of a subscription barrier.所有文章在阅读端免费，2025 年金色开放获取比例为 100%，作者支付文章处理费，读者一侧没有订阅门槛。
• The title sits in the Emerging Sources Citation Index rather than the flagship Science Citation Index Expanded, a placing that still brings a Journal Impact Factor and three subject rankings each year.该刊归入 Emerging Sources Citation Index，尚未进入旗舰的 Science Citation Index Expanded，这一版别每年仍给出影响因子与三个学科排名。
• Neurosciences is the hardest of the three categories, and there the journal holds 266th place among 330 titles, a fourth quartile position in the 2025 release, while its two other categories sit a step higher.神经科学是三个类目中最难的一档，2025 年该刊在 330 种期刊中排第 266 位，落在第四四分位，另外两个类目则高出一档。
• Pharmacology and pharmacy places it 253rd of 356, psychiatry 187th of 293, both in the third quartile, so the clinical readership is served by a title that ranks in the middle of its field.药理学与药学类目里排 356 种中的第 253 位，精神病学类目 293 种中排第 187 位，两者都在第三四分位，临床读者面对的是一份处于领域中游的刊物。
• Impact factors have moved within a narrow band, 2.0 in 2023, 1.5 in 2024 and 1.9 in 2025, while the five-year figure of 2.0 suggests a steadier citation base than the annual number implies.影响因子在窄幅区间内移动，2023 年为 2.0，2024 年降到 1.5，2025 年回到 1.9，五年影响因子 2.0 说明被引基础比年度数字所显示的更平稳。
• Citations total 1,033 a year, output runs near 75 papers, the cited half-life is 3.6 years and the Journal Citation Indicator reaches 0.44, all of it consistent with a young and fast moving field.全年总被引 1033 次，年发文约 75 篇，被引半衰期 3.6 年，期刊引文指标 0.44，这些数字与一个年轻而移动迅速的领域相称。
• Crossref lists 736 registered DOIs for the title, from 44 papers in its first year to 105 in 2025, a curve that follows the widening of the journal's remit across basic and clinical work.Crossref 为这份刊物登记了 736 条 DOI，创刊年 44 篇，2025 年增至 105 篇，这条曲线与刊物在基础与临床两端不断拓宽的范围相合。

Editors

• Editorial authority rests with the society and production with the publisher, an arrangement that leaves scientific direction in Japanese hands while Wiley runs hosting, copy editing and distribution.学术权力归学会，生产环节归出版方，这一分工让科学方向留在日本学界手中，托管、文字编辑与发行则由 Wiley 承担。
• Manuscripts arrive through the publisher's online submission system, the same route used across the Wiley list, and authors track review status from a personal dashboard once the file is complete.稿件经由出版方的在线投稿系统进入，这条路与 Wiley 旗下其他期刊一致，文件齐备后作者可以在个人界面跟踪审理状态。
• A submission is first read for fit, and papers that lie outside neuropsychopharmacology or ignore the length rules are returned before any referee is approached, which keeps the queue short for the rest.来稿先看是否对口，偏离神经精神药理学或不合篇幅规定的稿子会在送审之前退回，其余稿件的排队因此不受拖累。
• Referees from outside the editorial board then report on methods, statistics and claims, and a revision is expected before any decision, with further rounds where the reports conflict.编委之外的审稿人随后就方法、统计与结论提出意见，作者须修改后才进入裁决，意见相左时会追加一轮。
• Decisions rest with the handling editor, who weighs the reports against the journal's readership, and the reasoning is passed back in the decision letter rather than left implicit.裁决由处理编辑作出，他要把审稿意见与刊物的读者面放在一起权衡，判断理由随决定信一并寄回，避免让作者自行揣测。
• Brief Reports give short studies a separate track, useful for replication attempts, negative findings and small case series that would be stretched by a full article format.Brief Report 为短篇研究单设通道，重复实验、阴性结果与小型病例系列都可以走这条路，不必勉强撑成完整论文。
• Full articles carry the usual apparatus, an introduction that states the question, methods with drug doses and statistical models, results and a discussion that admits the limits of the design.完整论文要带齐常规部件，引言点明问题，方法写清给药剂量与统计模型，结果之外还要有一段承认设计局限的讨论。
• Reviewers of review articles look for a stated search strategy, explicit inclusion criteria and a synthesis that separates what the trials show from what the authors hope.综述的审稿人要求交检索策略与明确的纳入标准，还要求把试验已经显示的结果同作者的期待分开陈述。
• Trial reports must carry a registration number and a statement of ethics approval, animal work needs a committee reference, and human studies need consent procedures spelled out in the methods.试验报告须给出注册号与伦理批件，动物实验要注明伦理委员会编号，人体研究还要在方法里写明知情同意的取得方式。
• Funding and competing interests are declared for every author, and the funder information supplied at acceptance is registered with Crossref so that readers can trace it later.每位作者都要申报资助与利益冲突，录用时提交的资助信息会登记进 Crossref，读者日后可以追溯。
• Similarity checking runs on every submission before review, a step the publisher deposits openly in the Crossref record, so text overlap is caught at the desk rather than after publication.每篇来稿在送审前先过查重，出版方把这一环节登记在 Crossref 的公开记录里，文字重复在编辑台上就会被拦下，不必等到发表之后。
• Corrections, retractions and version updates follow a published policy that is also lodged with Crossref, which keeps the record of a changed paper visible to anyone who cites it.更正、撤稿与版本更新按公开政策执行，这套政策同样登记在 Crossref，被改动的论文对引用者始终可见。